GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS

GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS

Background: Gilteritinib (XOSPATA ®, Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ADMIRAL trial, gilteritinib was compared with the standard of care in (R/R) acute myeloid leukemia...

Full description

Bibliographic Details
Main Authors:	Mehmet Hilmi DOGU, Ali Irfan Emre TEKGUNDUZ, Burak DEVECI, Gulten KORKMAZ, Melda COMERT, Omur Gokmen SEVINDIK, Osman YOKUS, Istemi SERIN
Format:	Article
Language:	English
Published:	PAGEPress Publications 2023-04-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	Gilteritinib acute myeloid leukemia early access real-life response prognosis
Online Access:	http://www.mjhid.org/index.php/mjhid/article/view/5305

Similar Items

PB1897: GILTERITINIB IN TURKEY: EARLY ACCESS PROGRAM RESULTS
by: Mehmet Hilmi Dogu, et al.
Published: (2023-08-01)

Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
by: Bocchia M, et al.
Published: (2022-04-01)

Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms
by: Man Li, et al.
Published: (2024-08-01)

Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia
by: Lisa Kim, et al.
Published: (2021-10-01)

LC-MS/MS characterization of stress degradation products of Gilteritinib and establishment of HPLC method for analysis of process related impurities of Gilteritinib
by: Sreenivasa Rao Katta, et al.
Published: (2024-04-01)

Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia
by: Qi Zhou, et al.
Published: (2025-02-01)

Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition
by: Kran Suknuntha, et al.
Published: (2020-12-01)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
by: Juanjuan Zhao, et al.
Published: (2019-09-01)

Sweet syndrome induced by FLT3 inhibitors: case report and literature review
by: Linhui Yang, et al.
Published: (2024-12-01)

Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
by: Chun-xiao Hou, et al.
Published: (2024-12-01)

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
by: Chao-Yue Sun, et al.
Published: (2022-06-01)

Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
by: Takahiro Kumode, et al.
Published: (2020-01-01)

The safety and efficacy of the re-administration of gilteritinib in a patient with FLT3-mutated R/R AML with CNS relapse: a case report
by: Yueru Ji, et al.
Published: (2024-07-01)

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
by: Dominique A. Garrison, et al.
Published: (2022-10-01)

The Time Has Come for Targeted Therapies for AML: Lights and Shadows
by: Alessandro Fiorentini, et al.
Published: (2020-01-01)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
by: Yvyin Zhang, et al.
Published: (2023-01-01)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
by: R. Iannotta, et al.
Published: (2022-01-01)

An LC-MS/MS Bioanalytical Assay for the Determination of Gilteritinib in Rat Plasma and Application to a Drug–Drug Interaction Study
by: Wang Q, et al.
Published: (2020-05-01)

A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice
by: Monica Messina, et al.
Published: (2024-12-01)

Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
by: Karam Ashouri, et al.
Published: (2024-04-01)

Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress
by: Xiaoli Hu, et al.
Published: (2020-06-01)

Emergence of Natural Killer Cell Large Granular Lymphocytes during Gilteritinib Treatment in Acute Myeloid Leukemia with FLT3-ITD Mutation
by: Shintaro Izumi, et al.
Published: (2020-09-01)

An UPLC–ESI–MS/MS Bioanalytical Methodology for the Quantification of Gilteritinib in Human Liver Microsomes: Application to In Vitro and In Silico Metabolic Stability Estimation
by: Mohamed W. Attwa, et al.
Published: (2023-04-01)

Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis
by: Jingmei Yang, et al.
Published: (2025-03-01)

The beginning of a new therapeutic era in acute myeloid leukemia
by: Christian Récher
Published: (2021-11-01)

Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
by: Chuhong Hu, et al.
Published: (2024-07-01)

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
by: Motoki Eguchi, et al.
Published: (2020-07-01)

Targeting TKI-Activated NFKB2-MIF/CXCLs-CXCR2 Signaling Pathways in FLT3 Mutated Acute Myeloid Leukemia Reduced Blast Viability
by: Huynh Cao, et al.
Published: (2022-04-01)

Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia
by: Meira Yisraeli Salman, et al.
Published: (2021-10-01)

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
by: Lindsey T. Brinton, et al.
Published: (2020-10-01)

A new approach in acute myeloid leukemia (AML): Samatya-predicting score
by: Istemi Serin, et al.
Published: (2022-01-01)

Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
by: Süreyya Yiğit Kaya, et al.
Published: (2023-01-01)

First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS)
by: Omur Gokmen Sevindik, et al.
Published: (2022-07-01)

A Rare Disease in the Differential Diagnosis of Chylothorax: Waldenström’s Macroglobulinaemia
by: İstemi Serin, et al.
Published: (2020-11-01)

Sweet’s syndrome associated with FLT3 inhibition
by: Riyad N.H. Seervai, MD, PhD, et al.
Published: (2024-12-01)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2020-10-01)

Regression of leukemia cutis with gilteritinib in a case of FLT3-positive acute myeloid leukemia
by: Andrea Duminuco, et al.
Published: (2022-09-01)

Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study
by: İstemi Serin, et al.
Published: (2021-02-01)

An unexpected situation in isolated nasopharyngeal mass differential diagnosis: Solitary extramedullary plasmacytoma
by: Istemi Serin, et al.
Published: (2020-11-01)

Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients
by: Fahri Sahin, et al.
Published: (2013-09-01)